CAR T-cell Therapy for Metastatic Breast Cancer
This study is testing a new type of immunotherapy called CAR T-cell therapy for people with metastatic breast cancer. Researchers are using your own immune cells, called T cells, and modifying them in the lab to create either huMNC2-CAR44 or huMNC2-CAR22 T cells. These modified cells are designed to specifically target a cancerous form of a protein called MUC1* found on breast cancer cells. The main goal is to see how safe these treatments are by tracking any side effects you might experience. To join, you must have a confirmed diagnosis of breast cancer. The study plans to enroll up to 69 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll up to 69 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Adverse events will be measured within 35 days after T cell infusion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joanne Mortimer, MD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse EventsWithin 35 days after T cell infusion
To determine the safety and maximally tolerated cell dose (MTD) and recommended phase 2 cell dose (RP2D) of ex vivo expanded autologous huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells for patients with advanced MUC1\* positive breast cancer using CTCAE version 5.0 and Lee criteria.